Expert Details

Oncology, Hematology

ID: 735972 Ohio, USA

ACADEMIC BIO SKETCH: Expert holds the rank of Professor of Hematology/Oncology, is a 33 year veteran of academic medicine, a key opinion leader and skilled principal investigator of over 200 clinical trials and has published over 100 peer-reviewed articles in major scientific and clinical medical journals. Over the past 3 decades, she has served on the faculties of Mount Sinai Medical Center in New York, Albert Einstein Cancer Center in New York, Roswell Park Cancer Institute in Buffalo, the Barrett Cancer Center of the University of Cincinnati and The Dana Farber Cancer Center of Harvard University. Expert has also served in several administrative capacities including the Director of the SWOG Clinical Trial Cooperative Group and the Director of Infusion Services at the Barrett Cancer Center. Over her 33 years in clinical practice, Expert has treated thousands of patients with solid tumors, hematologic malignancies and hematologic disorders and has also served on NCCCN panels to establish best practice pathway algorithms based on evidence-based trial data. Throughout her career, Expert has served as analyst and consultant to the pharmaceutical industry, early bio-tech start-ups and the investment community relative to investigational drugs and their clinical development. At present, Expert is CEO of her own practice, a practice which provides second opinions for rare and complex cancer cases, offers medical intelligence to the Pharma and Investment communities as well as legal expert witness services.

LEGAL BIO SKETCH: MEDICAL MALPRACTICE I served as expert witness in 2 malpractice cases in the setting of clinical management of early prostate cancer, dating to 2003 and 2005. For each, I wrote a declaration and was deposed. These cases were settled and did not go to trial.
INTELLECTUAL PROPERTY In 2014, I was retained, in a patent dispute where I served as an expert witness on the side of the patent owner. The case involved a patent dispute, which is used to treat 1.) hypercalcemia and 2.) treat bone metastases. In 2016, I functioned as an expert witness in a patent despite where the petitioner and ___was the patent owner and the drug in question was Fulvestrant, an estrogen receptor antagonist. After submitting a declaration, the case was settled. I also worked on a case where I wrote several declarations and assume that the case was settled since this work was completed in 2015. In 2017, I was retained as an expert witness in a patent dispute by the firm on the side of (patent owner) vs (petitioner). I have continued to assist with their patents and at present, I previously this year, assisted as expert witness in a patent dispute. At present, I am not retained or under contract. *More examples available upon request.

Request Expert

Education

Year	Degree	Subject	Institution
Year: 1982	Degree: MD	Subject: Medicine	Institution: Tufts University School of Medicine, Boston MA

Work History

Years	Employer	Title	Department
Years: 2015 to Present	Employer: Undisclosed	Title: Professor of Medical Oncology and CEO	Department: Medical Oncology and Hematology/Oncology
Responsibilities: I am CEO of a combo medical oncology/Hematology practice where 1.) I provide second opinion consultations on rare and/or complicated cancer cases as well as 2.) functioning as a consultant to pharma and financial services with regard to medical intelligence and finally, 3.) serve as an expert witness in numerous cases from malpractice to intellectual property to breach of contract.
Years	Employer	Title	Department
Years: 2013 to 2014	Employer: Dana Farber Cancer Center	Title: Clinician	Department: Hematology/Oncology
Responsibilities: I functioned as a Hematologist/Oncologist, caring for patients with solid tumors, hematologic malignancies and non-malignant hematologic disorders.
Years	Employer	Title	Department
Years: 2012 to 2013	Employer: Saint Louis University Hospital and Medical Center	Title: Professor of Medicine	Department: Hematology/Oncology
Responsibilities: I functioned as a Hematologist/Oncologist, caring for patients with solid tumors, hematologic malignancies and non-malignant hematologic disorders.
Years	Employer	Title	Department
Years: 2003 to 2012	Employer: University of Cincinnati Medical Center and the Barrett Cancer Center	Title: Associate Professor of Medicine/Hematology/Oncology	Department: Department of Hematology/Oncology
Responsibilities: I functioned as a Hematologist/Oncologist, caring for patients with solid tumors, hematologic malignancies and non-malignant hematologic disorders.

Career Accomplishments

Associations / Societies
Professor of Medical Oncology/Hematology for 33 years, published over 100 clinical papers in peer reviewed journals, served as principal investigator in over 100 clinical trials, served as panelist for NCCN, key-opinion leader in medical oncology/Hematology, served as consultant to Pharma and financial services with regard to medical intelligence. Professional Societies: American Society of Hematology, Member American Society of Clinical Oncology, Member Cancer and Leukemia B (CALGB), Member Eastern cooperative Group (ECOG), Member Phi Delta Epsilon Fraternity, Member American College of Physicians, Member National Kidney Cancer Association, Member, Editorial Advisory Board SWOG, Member Editorial Activities: Cancer Transfusion Southern Journal of Medicine Journal of Urology American Journal of Medical Sciences

Associations / Societies

Professor of Medical Oncology/Hematology for 33 years, published over 100 clinical papers in peer reviewed journals, served as principal investigator in over 100 clinical trials, served as panelist for NCCN, key-opinion leader in medical oncology/Hematology, served as consultant to Pharma and financial services with regard to medical intelligence.

Professional Societies:
American Society of Hematology, Member
American Society of Clinical Oncology, Member
Cancer and Leukemia B (CALGB), Member
Eastern cooperative Group (ECOG), Member
Phi Delta Epsilon Fraternity, Member
American College of Physicians, Member
National Kidney Cancer Association, Member, Editorial Advisory Board
SWOG, Member

Editorial Activities:
Cancer
Transfusion
Southern Journal of Medicine
Journal of Urology
American Journal of Medical Sciences

Licenses / Certifications
MD. Liceensed in OH and NY state (active). Inactive in CT and MO

Professional Appointments
1989-1991: on faculty at Mt Sinai Medical Center in NEW YORK CITY 1991-1998: Assistant Professor at Montefiore University Hospital at Albert Einstein School of Medicine 1998-2003: Associated Professor of Medicine at Roswell Park Cancer Institute 2003-2012: Professor of Medicine at Barrett Cancer Center of University of Cincinnati Medical Center 2012-2013: Professor of Medicine at Saint Louis University Medical Center 2014-2015: Clinician at Dana Farber Cancer Center 2015-present: Expert M.D. LLC

Professional Appointments

1989-1991: on faculty at Mt Sinai Medical Center in NEW YORK CITY
1991-1998: Assistant Professor at Montefiore University Hospital at Albert Einstein School of Medicine
1998-2003: Associated Professor of Medicine at Roswell Park Cancer Institute
2003-2012: Professor of Medicine at Barrett Cancer Center of University of Cincinnati Medical Center
2012-2013: Professor of Medicine at Saint Louis University Medical Center
2014-2015: Clinician at Dana Farber Cancer Center
2015-present: Expert M.D. LLC

Awards / Recognition
Webster Prize Amherst College, Undergraduate Thesis Simpson Fellowship, Tufts University School of Medicine, Scholarship based on GPA Hampden Scholarship, Tuft University School of Medicine, Scholarship based on GPA Third Prize awarded at basic investigators research symposium, Albert Einstein college of Medicine, Third prize for best scientific paper Certificate of recognition, Roswell Park, Excellence in clinical practice

Awards / Recognition

Webster Prize Amherst College, Undergraduate Thesis
Simpson Fellowship, Tufts University School of Medicine, Scholarship based on GPA
Hampden Scholarship, Tuft University School of Medicine, Scholarship based on GPA
Third Prize awarded at basic investigators research symposium, Albert Einstein college of Medicine, Third prize for best scientific paper
Certificate of recognition, Roswell Park, Excellence in clinical practice

Medical / Professional
Committee Service: Local Transfusion Committee Montefiore Hospital/Albert Einstein College of Medicine, Member Cancer Center Protocol Review Committee Albert Einstein Cancer Center, Vice Chair Cancer Center Protocol Audit Committee Albert Einstein Cancer Center, Coordinator Hematology Malignancy Working Group Montefiore Hospital/Albert Einstein, Member Breast Malignancy Affinity Group, Member CME Advisory Board Roswell Park Cancer Institute, Member Morbidity and Mortality Committee Roswell Park Cancer Institute, Member Quality Improvement Committee Roswell Park, Member IRB Roswell Park, Member Hematology/Oncology Grand Rounds University of Cincinnati Director, Coordinator and Master of Ceremonies Scientific Review Protocol Committee University of Cincinnati, Member Ethics Committee University of Cincinnati, Co-Chair Hematology/Oncology Clinical Research Forum University of Cincinnati *Many more positions available upon request.

Medical / Professional

Committee Service: Local
Transfusion Committee
Montefiore Hospital/Albert Einstein College of Medicine, Member
Cancer Center Protocol Review Committee
Albert Einstein Cancer Center, Vice Chair
Cancer Center Protocol Audit Committee
Albert Einstein Cancer Center, Coordinator
Hematology Malignancy Working Group
Montefiore Hospital/Albert Einstein, Member
Breast Malignancy Affinity Group, Member
CME Advisory Board
Roswell Park Cancer Institute, Member
Morbidity and Mortality Committee
Roswell Park Cancer Institute, Member
Quality Improvement Committee
Roswell Park, Member
IRB
Roswell Park, Member
Hematology/Oncology Grand Rounds
University of Cincinnati
Director, Coordinator and Master of Ceremonies
Scientific Review Protocol Committee
University of Cincinnati, Member
Ethics Committee
University of Cincinnati, Co-Chair
Hematology/Oncology Clinical Research Forum
University of Cincinnati
*Many more positions available upon request.

Publications and Patents Summary
Over 100 peer reviewed publications in the area of Hematology and Medical Oncology.

Additional Experience

Expert Witness Experience
LEGAL BIO SKETCH: Expert M.D. I. MEDICAL MALPRACTICE I served as expert witness in 2 malpractice cases in the setting of clinical management of early prostate cancer, dating to 2003 and 2005. For each, I wrote a declaration and was deposed. These cases were settled and did not go to trial. II. INTELLECTUAL PROPERTY In 2014, I was retained by K and L Gate, the petitioner, in a patent dispute where I served as an expert witness on the side of Par Sterile Products LLC/ACCORD HEALTH CARE INC, vs Novartis, the patent owner. The case involved a patent dispute over the bisphosphonate, Zometa, which is used to treat 1.) hypercalcemia and 2.) treat bone metastases. I am no longer working for K and L Gates. In 2016, I functioned as an expert witness for Perkins and Coie in a patent despite where Mylan Pharmaceuticals INC was the petitioner and ASTRAZENICA AB was the patent owner and the drug in question was Fulvestrant, an estrogen receptor antagonist. After submitting a declaration, the case was settled. I also worked for Perkins and Coie on a case where the petitioner was Dr. Reddy’s Lab and the patent owner was Celgene. I wrote several declarations and assume that the case was settled since this work was completed in 2015. I no longer work for Perkins and Coie. In 2017, I was retained as an expert witness in a patent dispute by the firm of Wilmer/Hale on the side of Genentech (patent owner) vs Hospira (petitioner) regarding Herceptin. I have continued to assist Wilmer/Hale with their Herceptin patents and at present, I previously this year, assisted as expert witness in a patent dispute between on the side of Genentech vs AMGEN. At present, I am not retained or under contract with Wilmer/Hale In early 2018, I was retained by the Sprigings Intellectual Property Law Firm of Toronto, Canada in a patent dispute between Celgene, patent owner and Dr. Reddy’ laboratory, the petitioner, involving multiple patents for the drug Revlamid which is utilized to treat a variety of hematologic malignancies. After providing written declarations, I was informed by Sprigings that Dr. Reddy decided NOT to pursue the case to an inter-parties review. I am no longer working for Sprigings. in 2018, I was retained by Irell and Manella on the side of Genentech/Biogen, the patent owner, in a patent dispute with Pfizer, the petitioner regarding the cancer drug RITUXAN which is used to treat B-cell malignancies. I wrote a declaration, was deposed. At present, I am not under contract or retained by Irell and Manella. III. BREACH OF CONTRACT In 7/2019 I was retained by Diamond and McCarthy in a breach of contract dispute on the side of AURORA BIOTECH vs Baylor University. At present, I am working on this case.

Expert Witness Experience

LEGAL BIO SKETCH: Expert M.D.
I. MEDICAL MALPRACTICE
I served as expert witness in 2 malpractice cases in the setting of clinical management of early prostate cancer, dating to 2003 and 2005. For each, I wrote a declaration and was deposed. These cases were settled and did not go to trial.
II. INTELLECTUAL PROPERTY
In 2014, I was retained by K and L Gate, the petitioner, in a patent dispute where I served as an expert witness on the side of Par Sterile Products LLC/ACCORD HEALTH CARE INC, vs Novartis, the patent owner. The case involved a patent dispute over the bisphosphonate, Zometa, which is used to treat 1.) hypercalcemia and 2.) treat bone metastases. I am no longer working for K and L Gates.
In 2016, I functioned as an expert witness for Perkins and Coie in a patent despite where Mylan Pharmaceuticals INC was the petitioner and ASTRAZENICA AB was the patent owner and the drug in question was Fulvestrant, an estrogen receptor antagonist. After submitting a declaration, the case was settled. I also worked for Perkins and Coie on a case where the petitioner was Dr. Reddy’s Lab and the patent owner was Celgene. I wrote several declarations and assume that the case was settled since this work was completed in 2015. I no longer work for Perkins and Coie.
In 2017, I was retained as an expert witness in a patent dispute by the firm of Wilmer/Hale on the side of Genentech (patent owner) vs Hospira (petitioner) regarding Herceptin. I have continued to assist Wilmer/Hale with their Herceptin patents and at present, I previously this year, assisted as expert witness in a patent dispute between on the side of Genentech vs AMGEN. At present, I am not retained or under contract with Wilmer/Hale
In early 2018, I was retained by the Sprigings Intellectual Property Law Firm of Toronto, Canada in a patent dispute between Celgene, patent owner and Dr. Reddy’ laboratory, the petitioner, involving multiple patents for the drug Revlamid which is utilized to treat a variety of hematologic malignancies. After providing written declarations, I was informed by Sprigings that Dr. Reddy decided NOT to pursue the case to an inter-parties review. I am no longer working for Sprigings.
in 2018, I was retained by Irell and Manella on the side of Genentech/Biogen, the patent owner, in a patent dispute with Pfizer, the petitioner regarding the cancer drug RITUXAN which is used to treat B-cell malignancies. I wrote a declaration, was deposed. At present, I am not under contract or retained by Irell and Manella.
III. BREACH OF CONTRACT
In 7/2019 I was retained by Diamond and McCarthy in a breach of contract dispute on the side of AURORA BIOTECH vs Baylor University. At present, I am working on this case.

Training / Seminars
11/6/ 2004 Annual Greater Cincinnati Prostate Cancer Forum presented by the Barrett Cancer Center Conference panelist 3/25/2006 University of Cincinnati Cancer Education, Knowledge for Life, “Prostate Cancer: Frequently asked questions and answers”. Conference panelist 7/22/2006 First Annual University of Cincinnati Genitourinary Symposium: “Novel Targeted Therapies for the Treatment of Genitourinary Malignancies’. Course Director 7/21/2007 Second Annual university if Cincinnati Genitourinary symposium: “Overview of Novel Targeted Therapies for the Treatment of Genitourinary Malignancies”. Course Director and Speaker 7/26/2008 Third Annual University of Cincinnati Genitourinary Symposium: New Directions in the Treatment of Genitourinary Malignancies. Expert: Course Director and speaker, presenting “Overview of Targeted Therapies” Course Director and Speaker 7/26/2009 Fourth Annual University of Cincinnati Genitourinary Symposium: Evolving Treatment Paradigms for Genitourinary Malignancies. Expert: Course Director and Speaker. Presenting "Review of New Targeted Agents for the Treatment of Advanced Renal Cell Carcinoma". Course Director and Speaker 2/17/2007 University of Cincinnati Community Cancer Education Day- Knowledge for Life. Expert on “Prostate Cancer: Frequently Asked Questions and Answers”. Conference panelist 9/10/1999 Medical Oncology Syllabus Review Lecture, “Metastatic Melanoma”. Roswell Park Cancer Institute. Buffalo, New York Lecturer Local Invited Presentations 8/1/1991 Medical Research Seminar, “Mechanisms of Anti-Tumor Activity of IL-2 and IL-6: The Relationship Between the Hemostasis and Immune Systems”. Vermont Comprehensive Cancer Center, Burlington, VT. 9/5/1991 Oncology Research Seminar, “Mechanisms of Anti-Tumor Activity of IL-2 and IL-6: The Relationship Between the Hemostatic and Immune systems”. Winthrop-University Hospital, Minneola, N.Y. 2/21/1994 Symposium sponsored by Sandoz Pharmaceuticals. “Mechanisms of anti-tumor activity of IL-2 and IL-6. The Relationship between the Hemostatic and Immune Systems”. East Hanover, N.J. 12/10/1994 Medical Grand Rounds, “Platelet Activation Induced by IL-6: Evidence for a Mechanism Involving Arachidonic Acid Metabolism”. Montefiore University Hospital, Bronx, N.Y. 12/20/1994 Oncology Grand Rounds, “The Effect of IL-6 on Platelet Function: In Vitro and In vivo Studies.” Montefiore Hospital, Bronx, New York. 2/7/1995 Guest Lecturer, “The Role of Platelets in the Metastatic Process.” February 1995. Carol Solar Abbani Foundation Annual Meeting, New York, N.Y. 3/15/1995 Oncology Grand Rounds, “Autologous Immunomodulation.” March 1995. Department of Oncology, Montefiore Hospital, Bronx, New York. 5/6/1995 Oncology Grand Rounds, “Cytokine Interactions among Hematopoietic Cells.” May 1995. Weiler Hospital of the Albert Einstein College of Medicine, Bronx, N.Y 1/29/1996 Guest Lecturer, “Characterization of Immunorelated GPIb Expression by Myelogenous Leukemia Cells.” National Leukemia Research Association Annual New York Chapter Meeting, Garden City, N.Y. 1/20/1997 Hematology Grand Rounds, “Human Breast Carcinoma Cells Synthesize a Protein Immunorelated to Platelet GPIb with Different Functional Properties". Montefiore Hospital, Division of Hematology, Bronx, N.Y. 4/22/1997 Hematology Grand Rounds, “Human Breast Carcinoma Cells Synthesize a Protein Immunorelated to Platelet GPIb with Different Functional Properties”. Mount Sinai Hospital, Division of Hematology, New York, N.Y. 4/13/1997 Oncology Grand Rounds, “High-Dose Bolus Interleukin-2: A Fourth Treatment Modality for Advanced Renal cell carcinoma”, Stanley S. Scott Cancer Center, LSUMC, New Orleans, LA 9/5/1997 Research Seminar, “High-Dose Bolus Interleukin-2: A Forth Treatment Modality for Advanced Renal Cell Carcinoma”. F. Lee Moffitt Cancer Center, Tampa, FL. 2/26/1998 Clinical Research Seminar, “High-Dose Bolus Interleukin-2: A Fourth Treatment Modality for Advanced Renal Cell Carcinoma”. Ireland Cancer Center of the Case Western Reserve university. Division of Hematology/Oncology, Cleveland, OH 4/19/1998 Oncology Grand Rounds, “High-Dose Bolus Interleukin-2: A Fourth Treatment Modality for Advanced Renal Cell Carcinoma”. University of Minnesota, Division of Transplant, Hematology and oncology, Minneapolis, MN. 5/2/1998 Cadenza Foundation Invited Guest Lecture, “Human Breast Carcinoma Cells Synthesize a Protein Immunorelated to platelet GPIb with Different Functional Properties. Thomas Jefferson School of Medicine, Philadelphia, Pennsylvania. 6/5/1998 Oncology Grand Rounds, “High-Dose Bolus Interleukin-2: A Fourth Treatment modality for Advanced Renal Cell Carcinoma”. Department of Medicine, Roswell Park Cancer Institute. Buffalo, N.Y. 2/7/1999 Chiron-Sponsored Seminar. “High-Dose Bolus Interleukin-2: A Fourth Treatment Modality for advanced renal cell carcinoma. Buffalo, New York 5/27/1999 Hematology/Oncology Grand rounds. “High Dose Bolus Interleukin-2: A Fourth Treatment Modality for Advanced Renal Cell carcinoma”. Syracuse University, Syracuse, N.Y. 8/9/1999 Basic Seminar: “The Role of Tumor GPIb and Plasma von Willebrand’s Factor in Adhesive Interactions Regulating Metastasis Formation”. Roswell Park Cancer Institute, Grace Cancer Drug Center; Buffalo, N.Y. 9/10/1999 Medical Grand Rounds, “The Role of Tumor GPIb and Plasma von Willebrand’s Factor in Adhesive Interactions Regulating Metastasis Formation”. Roswell Park Cancer Institute. Buffalo, N.Y. 4/18/2001 Medical Grand Rounds. "High-Dose Bolus Interleukin-2: A Fourth Treatment Modality for Advanced Renal Cell Carcinoma.” Erie County Medical Center, Department of Urology, Buffalo, New York. 3/12/2003 Medical Grand Rounds. "High-Dose Bolus Interleukin-2: A Fourth Treatment Modality for Advanced Renal cell Carcinoma”. Milton S. Hershey Cancer Center, Hershey, PA 4/17/2003 Division of Hematology/Oncology Grand Rounds, “High Dose Bolus Interleukin-2: A Forth Treatment Modality for Advanced Renal cell Carcinoma”. University of Cincinnati, Cincinnati OH. 4/25/2003 Division Seminar “Treatment Modalities for Advanced Renal Cell Cancer.” University of Cincinnati Medical Center. Cincinnati, OH. 2/11/2004 Department of Radiation Oncology Grand Rounds, “An Overview of High Dose IL-2 & New Therapeutic Treatment Modalities for Advanced Renal Cell Carcinoma”. Barrett Cancer Center, University of Cincinnati, Cincinnati, OH 2/13/2004 Division of Hematology/Oncology Grand Rounds, “An Overview of High Dose IL-2 and New Therapeutic Modalities for the Treatment of Advanced Renal Cell Carcinoma”. University of Cincinnati medical Center, Cincinnati OH 2/18/2004 Department of Surgery Grand Rounds at Cincinnati University Hospital, “Overview of the medical genitourinary Oncology Program at University Hospital”. University of Cincinnati, Cincinnati, OH 7/14/2004 Department of Internal Medicine Grand Rounds. University of Cincinnati Medical Center. “An Overview of High Dose IL-2; New Therapeutic Treatment Modalities for Advanced Renal Cell Carcinoma”. University of Cincinnati, Cincinnati, OH 8/6/2004 Division of Hematology/Oncology Grand Rounds. Fellow and Resident Lecture Series: “Up-Date on Prostate Cancer Management and New Approaches to Treatment.” University of Cincinnati, Cincinnati, OH. 11/17/2004 4th Annual Greater Cincinnati Prostate Cancer Forum, “Treatments for Hormone Resistant Prostate Cancer”. Cincinnati Marriot Northeast Mason, OH. 6/5/2005. Division of Hematology/Oncology Grand Rounds, American Society of Clinical Oncology Annual Meeting Proceedings. “Update on the Treatment and Management of Renal Cell Carcinoma”. University of Cincinnati, Cincinnati, OH 12/6/2005 Prostate Cancer Working Group Symposium. 12/05. “The Role of Chemotherapy in advanced Prostate Cancer”. Kingsgate Marriott Conference Center, Cincinnati, OH 6/15/2006 Division of Medicine Departmental Meeting. June 2006. “An Overview of High Dose Interleukin-2 and New Therapeutic Modalities for the Treatment of Advanced Renal Cell Carcinoma”. University of Cincinnati, Cincinnati, OH 8/10/2006 Division of Hematology/Oncology Grand Rounds. Fellow and Resident Lecture Series: “Up-date on Prostate Cancer Management. New Approaches to Treatment”. University of Cincinnati, Cincinnati, OH. 8/22/2006 Division of Hematology/Oncology Grand Rounds, “Management of High Dose IL-2”. University of Cincinnati, Cincinnati, OH 8/28/2007 Division of Hematology/Oncology Grand Rounds. Fellow and Resident Lecture Series. “Review of Prostate Cancer Management and New Approaches to Treatment”. University of Cincinnati, Cincinnati, OH 9/5/2007 Division of Hematology/Oncology Grand Rounds, “High Dose IL-2 Management for Renal Cell Carcinoma. Identifying Appropriate Candidates for Treatment”. University of Cincinnati, Cincinnati, OH. 9/14/2007 Division of Hematology/Oncology Grand Rounds. Fellow and Resident Lecture Series. “Review of Prostate cancer Management and New Approaches to Treatment”. University of Cincinnati, Cincinnati, OH 9/19/2007 Division of Urology Grand Rounds, “An Overview of New Therapeutic Modalities for the Treatment of Metastatic Renal Cell Carcinoma”. University of Cincinnati, Cincinnati, OH 5/3/2008 Overview of Prostate and RCC. Speaker at University of Cincinnati Community Cancer Education day. University Point, West Chester,. OH 6/22/2008 Hematology/Oncology Grand Rounds. Division of Hematology/Oncology Grand Rounds, “Current Trends in the Treatment of Advanced Melanoma”. University of Cincinnati, Cincinnati, OH 9/5/2009 Grand Rounds Division of Hematology/Oncology: “Clinical Management of High Dose Interleukin-2”. University of Cincinnati, Cincinnati, OH 8/20/2009 Faculty Speaker for Regional GU Symposium, "Evaluating and Treating Genitourinary Malignancies, Evolving Treatment Paradigms in Advanced Renal Cell carcinoma”. Cincinnati Marriott in Mason OH 11/18/2009 Urology Grand Rounds. University of Cincinnati. “Prostate Cancer Up-Date”. University of Cincinnati, Cincinnati, OH 9/11/2010 Grand Rounds, Division of Hematology/Oncology. “New Clinical Strategies for the Treatment of Prostate Cancer”. University of Cincinnati, Cincinnati, OH 2/10/11 Genitourinary Research 2011 Symposium. 2/10/2011. "Dose Intensity High dose Interleukin-2: A Strategy for Improved Patient Outcomes.” Kingsgate Marriot, University of Cincinnati, Cincinnati, OH 3/8/2012 Hematology/Oncology Rounds. “Evolving Treatment Paradigms in Renal Cell Carcinoma”. Saint Louis University, St. Louis, MO 4/25/2012 Hematology/Oncology Grand Rounds at Mayo Clinic. “Metastatic Melanoma: New paradigms for Targeted Treatment”. Scottsdale, AZ 5/17/2011 Dinner Lecture sponsored by Prometheus: "Overview of High Dose Interleukin-2 in the Age of Targeted Therapy”. Cincinnati, OH 5/18/2012 Faculty Lecture Series. "Management of Testicular Tumors: A Standard for Success with Cytotoxic Chemotherapy”, University of Cincinnati, Cincinnati, OH 6/5/2012 Dinner Lecture sponsored by Prometheus: “Evolving Treatment Paradigms in Renal Cell Carcinoma”. Louisville KY 6/6/2012 Dinner Lecture sponsored by Prometheus: “Evolving Treatment Paradigms in Renal Cell Carcinoma”, Lexington, KY. 10/9/2012 Hematology/Oncology Grand Rounds. “New Clinical Strategies for the Treatment of Prostate Cancer”. Saint Louis, MO 1/20/2013 Dinner lecture sponsored by Medivation. “Enzalutamide, A New Therapeutic Option for Patients with Metastatic Prostate Cancer. Cape Girardeau, MO. 2/13/2013 Hematology/Oncology Grand Rounds. New Treatment Paradigms for Advanced Melanoma”. Saint Louis MO.

Training / Seminars

11/6/ 2004 Annual Greater Cincinnati Prostate Cancer Forum presented by the Barrett Cancer Center Conference panelist
3/25/2006 University of Cincinnati Cancer Education, Knowledge for Life, “Prostate Cancer: Frequently asked questions and answers”. Conference panelist
7/22/2006 First Annual University of Cincinnati Genitourinary Symposium: “Novel Targeted Therapies for the Treatment of Genitourinary Malignancies’. Course Director
7/21/2007 Second Annual university if Cincinnati Genitourinary symposium: “Overview of Novel Targeted Therapies for the Treatment of Genitourinary Malignancies”. Course Director and Speaker
7/26/2008 Third Annual University of Cincinnati Genitourinary Symposium: New Directions in the Treatment of Genitourinary Malignancies. Expert: Course Director and speaker, presenting “Overview of Targeted Therapies” Course Director and Speaker
7/26/2009 Fourth Annual University of Cincinnati Genitourinary Symposium: Evolving Treatment Paradigms for Genitourinary Malignancies. Expert: Course Director and Speaker. Presenting "Review of New Targeted Agents for the Treatment of Advanced Renal Cell Carcinoma". Course Director and Speaker
2/17/2007 University of Cincinnati Community Cancer Education Day- Knowledge for Life. Expert on “Prostate Cancer: Frequently Asked Questions and Answers”. Conference panelist
9/10/1999 Medical Oncology Syllabus Review Lecture, “Metastatic Melanoma”. Roswell Park Cancer Institute. Buffalo, New York Lecturer
Local Invited Presentations
8/1/1991 Medical Research Seminar, “Mechanisms of Anti-Tumor Activity of IL-2 and IL-6: The Relationship Between the Hemostasis and Immune Systems”. Vermont Comprehensive Cancer Center, Burlington, VT.
9/5/1991 Oncology Research Seminar, “Mechanisms of Anti-Tumor Activity of IL-2 and IL-6: The Relationship Between the Hemostatic and Immune systems”. Winthrop-University Hospital, Minneola, N.Y.
2/21/1994 Symposium sponsored by Sandoz Pharmaceuticals. “Mechanisms of anti-tumor activity of IL-2 and IL-6. The Relationship between the Hemostatic and Immune Systems”. East Hanover, N.J.

12/10/1994 Medical Grand Rounds, “Platelet Activation Induced by IL-6: Evidence for a Mechanism Involving Arachidonic Acid Metabolism”. Montefiore University Hospital, Bronx, N.Y.
12/20/1994 Oncology Grand Rounds, “The Effect of IL-6 on Platelet Function: In Vitro and In vivo Studies.” Montefiore Hospital, Bronx, New York.
2/7/1995 Guest Lecturer, “The Role of Platelets in the Metastatic Process.” February 1995. Carol Solar Abbani Foundation Annual Meeting, New York, N.Y.
3/15/1995 Oncology Grand Rounds, “Autologous Immunomodulation.” March 1995. Department of Oncology, Montefiore Hospital, Bronx, New York.
5/6/1995 Oncology Grand Rounds, “Cytokine Interactions among Hematopoietic Cells.” May 1995. Weiler Hospital of the Albert Einstein College of Medicine, Bronx, N.Y
1/29/1996 Guest Lecturer, “Characterization of Immunorelated GPIb Expression by Myelogenous Leukemia Cells.” National Leukemia Research Association Annual New York Chapter Meeting, Garden City, N.Y.
1/20/1997 Hematology Grand Rounds, “Human Breast Carcinoma Cells Synthesize a Protein Immunorelated to Platelet GPIb with Different Functional Properties". Montefiore Hospital, Division of Hematology, Bronx, N.Y.
4/22/1997 Hematology Grand Rounds, “Human Breast Carcinoma Cells Synthesize a Protein Immunorelated to Platelet GPIb with Different Functional Properties”. Mount Sinai Hospital, Division of Hematology, New York, N.Y.
4/13/1997 Oncology Grand Rounds, “High-Dose Bolus Interleukin-2: A Fourth Treatment Modality for Advanced Renal cell carcinoma”, Stanley S. Scott Cancer Center, LSUMC, New Orleans, LA
9/5/1997 Research Seminar, “High-Dose Bolus Interleukin-2: A Forth Treatment Modality for Advanced Renal Cell Carcinoma”. F. Lee Moffitt Cancer Center, Tampa, FL.
2/26/1998 Clinical Research Seminar, “High-Dose Bolus Interleukin-2: A Fourth Treatment Modality for Advanced Renal Cell Carcinoma”. Ireland Cancer Center of the Case Western Reserve university. Division of Hematology/Oncology, Cleveland, OH
4/19/1998 Oncology Grand Rounds, “High-Dose Bolus Interleukin-2: A Fourth Treatment Modality for Advanced Renal Cell Carcinoma”. University of Minnesota, Division of Transplant, Hematology and oncology, Minneapolis, MN.
5/2/1998 Cadenza Foundation Invited Guest Lecture, “Human Breast Carcinoma Cells Synthesize a Protein Immunorelated to platelet GPIb with Different Functional Properties. Thomas Jefferson School of Medicine, Philadelphia, Pennsylvania.
6/5/1998 Oncology Grand Rounds, “High-Dose Bolus Interleukin-2: A Fourth Treatment modality for Advanced Renal Cell Carcinoma”. Department of Medicine, Roswell Park Cancer Institute. Buffalo, N.Y.
2/7/1999 Chiron-Sponsored Seminar. “High-Dose Bolus Interleukin-2: A Fourth Treatment Modality for advanced renal cell carcinoma. Buffalo, New York
5/27/1999 Hematology/Oncology Grand rounds. “High Dose Bolus Interleukin-2: A Fourth Treatment Modality for Advanced Renal Cell carcinoma”. Syracuse University, Syracuse, N.Y.
8/9/1999 Basic Seminar: “The Role of Tumor GPIb and Plasma von Willebrand’s Factor in Adhesive Interactions Regulating Metastasis Formation”. Roswell Park Cancer Institute, Grace Cancer Drug Center; Buffalo, N.Y.
9/10/1999 Medical Grand Rounds, “The Role of Tumor GPIb and Plasma von Willebrand’s Factor in Adhesive Interactions Regulating Metastasis Formation”. Roswell Park Cancer Institute. Buffalo, N.Y.
4/18/2001 Medical Grand Rounds. "High-Dose Bolus Interleukin-2: A Fourth Treatment Modality for Advanced
Renal Cell Carcinoma.” Erie County Medical Center, Department of Urology, Buffalo, New York.
3/12/2003 Medical Grand Rounds. "High-Dose Bolus Interleukin-2: A Fourth Treatment Modality for Advanced Renal cell Carcinoma”. Milton S. Hershey Cancer Center, Hershey, PA
4/17/2003 Division of Hematology/Oncology Grand Rounds, “High Dose Bolus Interleukin-2: A Forth Treatment Modality for Advanced Renal cell Carcinoma”. University of Cincinnati, Cincinnati OH.
4/25/2003 Division Seminar “Treatment Modalities for Advanced Renal Cell Cancer.” University of Cincinnati Medical Center. Cincinnati, OH.
2/11/2004 Department of Radiation Oncology Grand Rounds, “An Overview of High Dose IL-2 & New Therapeutic Treatment Modalities for Advanced Renal Cell Carcinoma”. Barrett Cancer Center, University of Cincinnati, Cincinnati, OH
2/13/2004 Division of Hematology/Oncology Grand Rounds, “An Overview of High Dose IL-2 and New Therapeutic Modalities for the Treatment of Advanced Renal Cell Carcinoma”. University of Cincinnati medical Center, Cincinnati OH
2/18/2004 Department of Surgery Grand Rounds at Cincinnati University Hospital, “Overview of the medical genitourinary Oncology Program at University Hospital”. University of Cincinnati, Cincinnati, OH
7/14/2004 Department of Internal Medicine Grand Rounds. University of Cincinnati Medical Center. “An Overview of High Dose IL-2; New Therapeutic Treatment Modalities for Advanced Renal Cell Carcinoma”. University of Cincinnati, Cincinnati, OH
8/6/2004 Division of Hematology/Oncology Grand Rounds. Fellow and Resident Lecture Series: “Up-Date on Prostate Cancer Management and New Approaches to Treatment.” University of Cincinnati, Cincinnati, OH.
11/17/2004 4th Annual Greater Cincinnati Prostate Cancer Forum, “Treatments for Hormone Resistant Prostate Cancer”. Cincinnati Marriot Northeast Mason, OH.
6/5/2005. Division of Hematology/Oncology Grand Rounds, American Society of Clinical Oncology Annual Meeting Proceedings. “Update on the Treatment and Management of Renal Cell Carcinoma”. University of Cincinnati, Cincinnati, OH
12/6/2005 Prostate Cancer Working Group Symposium. 12/05. “The Role of Chemotherapy in advanced Prostate Cancer”. Kingsgate Marriott Conference Center, Cincinnati, OH
6/15/2006 Division of Medicine Departmental Meeting. June 2006. “An Overview of High Dose Interleukin-2 and New Therapeutic Modalities for the Treatment of Advanced Renal Cell Carcinoma”. University of Cincinnati, Cincinnati, OH
8/10/2006 Division of Hematology/Oncology Grand Rounds. Fellow and Resident Lecture Series: “Up-date on Prostate Cancer Management. New Approaches to Treatment”. University of Cincinnati, Cincinnati, OH.
8/22/2006 Division of Hematology/Oncology Grand Rounds, “Management of High Dose IL-2”. University of Cincinnati, Cincinnati, OH
8/28/2007 Division of Hematology/Oncology Grand Rounds. Fellow and Resident Lecture Series. “Review of Prostate Cancer Management and New Approaches to Treatment”. University of Cincinnati, Cincinnati, OH
9/5/2007 Division of Hematology/Oncology Grand Rounds, “High Dose IL-2 Management for Renal Cell Carcinoma. Identifying Appropriate Candidates for Treatment”. University of Cincinnati, Cincinnati, OH.
9/14/2007 Division of Hematology/Oncology Grand Rounds. Fellow and Resident Lecture Series. “Review of Prostate cancer Management and New Approaches to Treatment”. University of Cincinnati, Cincinnati, OH
9/19/2007 Division of Urology Grand Rounds, “An Overview of New Therapeutic Modalities for the Treatment of Metastatic Renal Cell Carcinoma”. University of Cincinnati, Cincinnati, OH
5/3/2008 Overview of Prostate and RCC. Speaker at University of Cincinnati Community Cancer Education day. University Point, West Chester,. OH
6/22/2008 Hematology/Oncology Grand Rounds. Division of Hematology/Oncology Grand Rounds, “Current Trends in the Treatment of Advanced Melanoma”. University of Cincinnati, Cincinnati, OH
9/5/2009 Grand Rounds Division of Hematology/Oncology: “Clinical Management of High Dose Interleukin-2”. University of Cincinnati, Cincinnati, OH
8/20/2009 Faculty Speaker for Regional GU Symposium, "Evaluating and Treating Genitourinary Malignancies, Evolving Treatment Paradigms in Advanced Renal Cell carcinoma”. Cincinnati Marriott in Mason OH
11/18/2009 Urology Grand Rounds. University of Cincinnati. “Prostate Cancer Up-Date”. University of Cincinnati, Cincinnati, OH
9/11/2010 Grand Rounds, Division of Hematology/Oncology. “New Clinical Strategies for the Treatment of Prostate Cancer”. University of Cincinnati, Cincinnati, OH
2/10/11 Genitourinary Research 2011 Symposium. 2/10/2011. "Dose Intensity High dose Interleukin-2: A Strategy for Improved Patient Outcomes.” Kingsgate Marriot, University of Cincinnati, Cincinnati, OH
3/8/2012 Hematology/Oncology Rounds. “Evolving Treatment Paradigms in Renal Cell Carcinoma”. Saint Louis University, St. Louis, MO
4/25/2012 Hematology/Oncology Grand Rounds at Mayo Clinic. “Metastatic Melanoma: New paradigms for Targeted Treatment”. Scottsdale, AZ
5/17/2011 Dinner Lecture sponsored by Prometheus: "Overview of High Dose Interleukin-2 in the Age of Targeted Therapy”. Cincinnati, OH
5/18/2012 Faculty Lecture Series. "Management of Testicular Tumors: A Standard for Success with Cytotoxic Chemotherapy”, University of Cincinnati, Cincinnati, OH
6/5/2012 Dinner Lecture sponsored by Prometheus: “Evolving Treatment Paradigms in Renal Cell Carcinoma”. Louisville KY
6/6/2012 Dinner Lecture sponsored by Prometheus: “Evolving Treatment Paradigms in Renal Cell Carcinoma”, Lexington, KY.
10/9/2012 Hematology/Oncology Grand Rounds. “New Clinical Strategies for the Treatment of Prostate Cancer”. Saint Louis, MO
1/20/2013 Dinner lecture sponsored by Medivation. “Enzalutamide, A New Therapeutic Option for Patients with Metastatic Prostate Cancer. Cape Girardeau, MO.
2/13/2013 Hematology/Oncology Grand Rounds. New Treatment Paradigms for Advanced Melanoma”. Saint Louis MO.

Other Relevant Experience
Other Professional Positions: Consultant, Merck Pharmaceutical: Evaluation of clinical and laboratory data related to COX-2 inhibitor. Course Director, Practical Reviews in Cancer Management. Monthly review of recent clinical studies in medical oncology Advisory Board Member National Kidney Cancer Association Course Director, First Annual University of Cincinnati Genitourinary Symposium Advisory Board Member Novartis (Interleukin-2) Course Director, Second Annual University of Cincinnati Genitourinary Symposium Member speaker bureau Bayer/Onyx Advisory Board Member Association of Community Cancer Center Course Director, Third Annual University of Cincinnati Genito-Urinary Symposium Principal Investigator of SWOG, University of Cincinnati and University of Saint Louis Advisory Board Member Pfizer Course Director, Fourth Annual University of Cincinnati Genitourinary Symposium Advisory Board Member Centacore-Ortho

Other Relevant Experience

Other Professional Positions:
Consultant, Merck Pharmaceutical: Evaluation of clinical and laboratory data related to COX-2 inhibitor.
Course Director, Practical Reviews in Cancer Management. Monthly review of recent clinical studies in medical oncology
Advisory Board Member National Kidney Cancer Association
Course Director, First Annual University of Cincinnati Genitourinary Symposium
Advisory Board Member Novartis (Interleukin-2)
Course Director, Second Annual University of Cincinnati Genitourinary Symposium
Member speaker bureau Bayer/Onyx
Advisory Board Member Association of Community Cancer Center
Course Director, Third Annual University of Cincinnati Genito-Urinary Symposium
Principal Investigator of SWOG, University of Cincinnati and University of Saint Louis
Advisory Board Member Pfizer
Course Director, Fourth Annual University of Cincinnati Genitourinary Symposium
Advisory Board Member Centacore-Ortho

Language Skills

Language	Proficiency
English	Fluent

Fields of Expertise

oncology, hematologic neoplasm, hematologic disease, breast cancer, cancer immunotherapy, bone cancer, gastrointestinal cancer, lung cancer, blood clotting disease, malignant melanoma, kidney cancer, head and neck cancer, brain tumor, sarcoma, adoptive cellular immunotherapy, leukemia, lymphoproliferative disorder, chronic lymphocytic leukemia, lymphoma, bladder cancer, prostate cancer, gynecologic oncology, skin cancer, cancer biology, cancer causation, cancer chemoprevention, cancer chemotherapeutic agent, cancer chemotherapy, cancer diagnosis, cancer epidemiology, cancer prognosis, cancer research, cancer treatment, cancer immunology, cancer, cancer physiology, intestinal cancer, colon cancer, colon cancer screening, colorectal cancer, liver cancer, missed cancer diagnosis, occupational cancer, oral cancer, pancreatic cancer, stomach cancer, skin cancer treatment, urologic cancer, cancer risk, precancerous condition, genetic disease, genetic mutation process

Request Expert

Expert Details

Oncology, Hematology

Education

Work History

Responsibilities:

Responsibilities:

Responsibilities:

Responsibilities:

Career Accomplishments

Additional Experience

Language Skills

Fields of Expertise